BOLD CLINICAL TRIALS
Two randomised controlled trials.1,2
Bold is being the first company to conduct two Level-1 comparative effectiveness trials. No SFA stent has performed better at 2-Years.1,2 No matter the lesion complexity. No matter the patient. See how it can make a difference in the fight against PAD.
Built for sustained drug release and efficient drug transfer.
Only the Eluvia™ Drug-Eluting Stent offers sustained drug release to match the restenotic process in the SFA, with the lowest drug-dose3 delivered by the most proven polymer.
Watch Prof. Y. Goueffic (Vascular Surgeon, France) presents the 12-Month results of the EMINENT RCT.
EMINENT Randomised Clinical Trial Results4
Eluvia DES demonstrated superior effectiveness over bare metal stents at 1-Year in the world's largest RCT of SFA stents.4
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.